Effect of an electronic nicotine delivery system with 0, 8, or /mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, controlled trial.

Plain-language guide to PMID 33857436 (2021): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 33857436
Journal: The Lancet. Respiratory medicine
Year: 2021
Study type: Randomized Controlled Trial
Authors: Cobb CO et al. (9 authors)
DOI: 10.1016/S2213-2600(21)00022-9
Registered trial: NCT02342795

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

National Institutes of Health, US Food and Drug Administration.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Multiple imputation with and without covariate adjustment was used in addition to sensitivity analyses.

How the Study Was Run

The researchers set it up as a randomized, double-blind and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.

The Therapeutic nicotine (patch, non-peptide) group and the comparison group ran side by side rather than switching.

The researchers did a four-arm, parallel-group, randomised controlled trial at two sites in the USA (Penn State University, Hershey, PA, and Virginia Commonwealth University, Richmond, VA).

The primary outcome was concentration of the tobacco-specific carcinogen metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL; urinary total) collected at randomisation and at 4, 12, and 24 weeks.

This trial is registered with ClinicalTrials.gov, NCT02342795.

What Was Measured

Topics PubMed links to this paper include Carcinogens, Electronic Nicotine Delivery Systems, Nicotine, Nitrosamines and Smoking Cessation.

What This Means in Plain Language

The paper is a randomized, double-blind and parallel-group study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (The Lancet. Respiratory medicine), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.